# First Line Treatment With Olaparib in Combination With Bevacizumab in HRD Positive Patients

> **NCT06121401** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **Mario Negri Institute for Pharmacological Research** · enrollment: 190 (estimated)

## Conditions studied

- Carcinoma, Ovarian Epithelial

## Interventions

- **DRUG:** Olaparib
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT06121401
- **Lead sponsor:** Mario Negri Institute for Pharmacological Research
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-09-15
- **Primary completion:** 2027-03-15
- **Final completion:** 2027-09-15
- **Target enrollment:** 190 (ESTIMATED)
- **Last updated:** 2025-09-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06121401

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06121401, "First Line Treatment With Olaparib in Combination With Bevacizumab in HRD Positive Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06121401. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*